- BMSystems will participate to BIO in Boston, June 18-21; and Bio-Europe in Hamburg November, 12-14.
- Munich,may 11-12, 2012: BMSystems' CSO François Iris, is invited as session chairman to the 8th International Workshop on Computational Neuropsychiatry: Sleep, Affective disorders and Schizophrenia - An integrated view.
- Press-Release-Feb-2012: Pherecydes Pharma secures a €1.2-million Defense agency funding for evaluating the use of bacteriophages against infected, antibiotic resistant burns.
Downloads
BMSystems European Commission Conference Presentation
The EC "From Systems Biology to Systems Medicine" report
Industrial biotech World cluster
Spin-off sites
CADI™ Research - Production
CADI™ programs to date. Internal & collaborative programs only, the contractual programs are confidential.
Bio-Modeling Systems R&D team has already conducted CADI™ programs in 7 areas of interest at various stages:
- Infection / Immunology: Antibacterial bio-agent7 ; Chronic Fatigue Syndrome2 ; Ebola virus ecology2 ; Hepatitis C1
- CNS: Creutzfeldt-Jakob4, Psychiatric disorders7 ; Biomarkers for MDD & schizophrenia1 ; Alzheimer disease1 ; Fibromyalgia1 ; Pain1 ; Migraine1 ; Multiple Sclerosis1
- Industrial biotech: Program Synthons: Collaborative research platform.
- Systemics: Breast cancer HRas4, Tamoxifen resistance4 , Metastasis mechanism3
- Tissue differentiation: Adipocytes growth control1, Mullerian regression4
- Metabolism: Hypercholesterolemia1, Metabolic Syndrome1.
- Targeted Variant Proteins: CADI™-TAPE Process7
1 : CADI™ compliance Ok ; 2: CADI™ Version 0 built ; 3: Independent Experimental validation Ok ; 4 Patented and/or published models ; 5: First Proof of Concept (POC) ; 6: Midscale or preclinical POC ; 7 Ready for business or already in business.